Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Cited In for PubMed (Select 21219297)

1.

PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.

Briest F, Grabowski P.

Theranostics. 2014 Jan 29;4(4):336-65. doi: 10.7150/thno.7851. eCollection 2014. Review.

2.

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab.

Hughes JB, Rødland MS, Hasmann M, Madshus IH, Stang E.

Pharmaceuticals (Basel). 2012 Jun 28;5(7):674-89. doi: 10.3390/ph5070674.

3.

Involvement of yeast HSP90 isoforms in response to stress and cell death induced by acetic acid.

Silva A, Sampaio-Marques B, Fernandes A, Carreto L, Rodrigues F, Holcik M, Santos MA, Ludovico P.

PLoS One. 2013 Aug 15;8(8):e71294. doi: 10.1371/journal.pone.0071294. eCollection 2013.

4.

Experimental approaches in the treatment of multiple myeloma.

Khan SA, Cohen AD.

Ther Adv Hematol. 2011 Aug;2(4):213-30. doi: 10.1177/2040620711410097.

5.

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.

Bambury RM, Rosenberg JE.

Front Pharmacol. 2013 Feb 6;4:3. doi: 10.3389/fphar.2013.00003. eCollection 2013.

6.

The Disease and Gene Annotations (DGA): an annotation resource for human disease.

Peng K, Xu W, Zheng J, Huang K, Wang H, Tong J, Lin Z, Liu J, Cheng W, Fu D, Du P, Kibbe WA, Lin SM, Xia T.

Nucleic Acids Res. 2013 Jan;41(Database issue):D553-60. doi: 10.1093/nar/gks1244. Epub 2012 Nov 28.

7.

Hyperthermia stimulates HIV-1 replication.

Roesch F, Meziane O, Kula A, Nisole S, Porrot F, Anderson I, Mammano F, Fassati A, Marcello A, Benkirane M, Schwartz O.

PLoS Pathog. 2012;8(7):e1002792. doi: 10.1371/journal.ppat.1002792. Epub 2012 Jul 12.

8.

Heat shock protein 90 inhibition: rationale and clinical potential.

Den RB, Lu B.

Ther Adv Med Oncol. 2012 Jul;4(4):211-8. doi: 10.1177/1758834012445574.

9.

Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo.

Sarkar S, Dutta D, Samanta SK, Bhattacharya K, Pal BC, Li J, Datta K, Mandal C, Mandal C.

Int J Cancer. 2013 Feb 1;132(3):695-706. doi: 10.1002/ijc.27687. Epub 2012 Jul 9.

10.

Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.

Peron M, Bonvini P, Rosolen A.

BMC Cancer. 2012 Jun 12;12:233. doi: 10.1186/1471-2407-12-233.

11.

DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Aronson LI, Davies FE.

Haematologica. 2012 Aug;97(8):1119-30. doi: 10.3324/haematol.2012.064923. Epub 2012 May 11. Review.

12.

The rapid and direct determination of ATPase activity by ion exchange chromatography and the application to the activity of heat shock protein-90.

Bartolini M, Wainer IW, Bertucci C, Andrisano V.

J Pharm Biomed Anal. 2013 Jan 25;73:77-81. doi: 10.1016/j.jpba.2012.03.021. Epub 2012 Mar 21.

13.

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C.

J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26.

14.

Evaluation of direct infusion-multiple reaction monitoring mass spectrometry for quantification of heat shock proteins.

Xiang Y, Koomen JM.

Anal Chem. 2012 Feb 21;84(4):1981-6. doi: 10.1021/ac203011j. Epub 2012 Jan 23.

15.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

16.

Hsp90 molecular chaperone inhibitors: are we there yet?

Neckers L, Workman P.

Clin Cancer Res. 2012 Jan 1;18(1):64-76. doi: 10.1158/1078-0432.CCR-11-1000. Review.

17.

Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice.

Ambade A, Catalano D, Lim A, Mandrekar P.

Hepatology. 2012 May;55(5):1585-95. doi: 10.1002/hep.24802. Epub 2012 Mar 18.

18.

Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101.

Braunstein MJ, Scott SS, Scott CM, Behrman S, Walter P, Wipf P, Coplan JD, Chrico W, Joseph D, Brodsky JL, Batuman O.

J Oncol. 2011;2011:232037. doi: 10.1155/2011/232037. Epub 2011 Sep 29.

19.

A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.

Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G.

Clin Cancer Res. 2011 Nov 1;17(21):6831-9. doi: 10.1158/1078-0432.CCR-11-0821. Epub 2011 Sep 9.

20.

ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.

Cervantes-Gomez F, Nimmanapalli R, Gandhi V.

J Pharmacol Exp Ther. 2011 Nov;339(2):545-54. doi: 10.1124/jpet.111.184903. Epub 2011 Aug 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk